Rising Use of Tezepelumab Reflects Changing Biologic Therapy Trends in Severe Asthma, Finds Study

The study, presented by Isabella Novoa Caicedo from Mayo Clinic and colleagues, examined how prescribing patterns for biologic therapies in severe asthma have shifted in routine clinical practice. Since the first biologic agent for severe asthma was approved in 2003, several additional targeted therapies have entered the market, expanding treatment options and influencing clinician choice. However, real-world data reflecting how these therapies are being adopted over time remains limited.

To address this gap, investigators conducted a retrospective observational analysis using prescription data from 7,015 patients treated within a large U.S. network of specialty allergy and asthma clinics between 2016 and 2025. Adults and adolescents with severe asthma were identified using ICD-10 diagnostic codes. The analysis focused on patients who had received at least one U.S. Food and Drug Administration–approved biologic therapy for asthma. Researchers tracked the first recorded prescription or injection of each biologic during the study period to assess initiation trends.    

The researchers concluded that biologic prescribing patterns in severe asthma have undergone significant transformation over the past decade. The rapid uptake of tezepelumab, in particular, highlights increasing clinical demand for therapies that can address non–type 2 inflammatory pathways, broadening treatment possibilities for patients whose disease does not fit the traditional T2-high profile.